Ensuring that patients receive full cardiac pharmacotherapy services: A pharmacist's call to arms

Annals of Pharmacotherapy

Volumn 40, Issue 12, 2006, Pages 2248-2250

  White, C Michael ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

Cardiovascular drugs; Pharmacotherapy services

Indexed keywords

CARDIOVASCULAR AGENT;

ANTICOAGULATION; CARDIOVASCULAR RISK; HEALTH CARE ACCESS; HEALTH CARE MANAGEMENT; HYPERLIPIDEMIA; HYPERTENSION; PATIENT CARE; PHARMACIST; PRESCRIPTION; PRIORITY JOURNAL; REVIEW;

CARDIOVASCULAR AGENTS; HUMANS; PATIENT COMPLIANCE; PATIENT EDUCATION; PHARMACEUTICAL SERVICES; PHARMACISTS; PROFESSIONAL ROLE;

EID: 33845613602     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H379     Document Type: Review

References (15)

1. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol 2003;41:56-61.
2. Samsa GP, Matachar DB, Goldstein LB, et al. Quality of anticoagulation management among patients with atrial fibrillation: results from a review of medical records from 2 communities. Arch Intern Med 2000;160:967-73.
3. National Committee for Quality Assurance. The state of health care quality 2005: industry trends and analysis, www.ncqa.org (accessed 2006 Jul 11).
4. Vittinghoff E, Shlipak MG, Varosy PD, et al. Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2003;138:81-9.
5. White CM. Prevention of suboptimal beta-blocker treatment in patients with myocardial infarction. Ann Pharmacother 1999;33:1063-72. DOI 10.1345/aph.18395
6. Lee DS, Tu JV, Juurlink DN, et al. Risk treatment mismatch in the pharmacotherapy of heart failure. JAMA 2005;294:1240-7.
7. Brown-Luzier A, Forrest A, Adelman M, Hawaii FI, Schentag JJ, Izzo JL. Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure. Am J Cardiol 1998; 82:465-9.
8. Straka RJ, Taheri R, Cooper SL, Tan AW, Smith AC. Assessment of hypercholesterolemia control in a managed care organization. Pharmacotherapy 2001;21:818-27.
9. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160: 459-67.
10. Chobanian AV, Bakris GI, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560-72.
11. Newby LK, LaPoint NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention in coronary artery disease. Circulation 2006;113:203-12.
12. White CM, Chow MSS. Cost impact and clinical benefits of focused rounding in the intensive care unit. Hosp Pharm 1998;33:419-23.
13. Folstad J, Caron MF, Cioffi ST, White CM. Controlling hyperlipidemia: the role of pharmacist managed clinics. Fed Pract 2003;20:20-8.
14. Schumock GT, Butler MG, Meek PD, Vermuleulen LC, Arondekar BV, Bauman JL. Evidence of the economic benefit of clinical pharmacy services: 1996-2000. Pharmacotherapy 2003;23:113-32.
15. American College of Clinical Pharmacy. Evidence of the value of the pharmacist. www.accp.com/position/paper6.pdf (accessed 2006 Aug 9).